Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibrx Biosciences (INBX) Non-Current Debt: 2023

Historic Non-Current Debt for Inhibrx Biosciences (INBX) over the last 1 years, with Dec 2023 value amounting to $207.0 million.

  • Inhibrx Biosciences' Non-Current Debt was N/A to $99.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $99.9 million, marking a year-over-year change of. This contributed to the annual value of $207.0 million for FY2023, which is N/A change from last year.
  • As of FY2023, Inhibrx Biosciences' Non-Current Debt stood at $207.0 million.
  • Inhibrx Biosciences' Non-Current Debt's 5-year high stood at $207.0 million during FY2023, with a 5-year trough of $207.0 million in FY2023.
  • Over the past 1 years, Inhibrx Biosciences' median Non-Current Debt value was $207.0 million (recorded in 2023), while the average stood at $207.0 million.